Home versus hospital care for diabetic eye swelling
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether receiving anti-VEGF injections for diabetic macular edema (DME) at home is as safe and effective as getting them in the hospital. You would use a home device to check your vision and eye scans, and a nurse would visit for injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have type 1 or type 2 diabetes.
- You can get to the hospital within 2 hours from home.
- You are willing to use a home vision tester and an eye scanner (OCT) after training.
- At least one eye has swelling from diabetes (DME) and vision between 20/32 and 20/320.
- Your eye has not had many anti-VEGF injections in the past year.
- You do not have other eye diseases that could affect vision, like glaucoma or cataract needing surgery soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
This study follows patients with diabetic eye swelling (a complication of diabetes affecting the macula, the part of your eye needed for detailed vision) who are receiving anti-VEGF injections—a standard treatment that reduces abnormal blood vessel growth. Researchers will measure how well your retina (the light-sensitive tissue in your eye) recovers and functions over time.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.